Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EC grants orphan drug status to Ipsen OBI-1
The orphan drug status would trigger a 10-year market exclusivity for OBI-1 in the European Union after its marketing approval. Ipsen licensed OBI-1 to Inspiration Biopharmaceuticals under an
The orphan drug status would trigger a 10-year market exclusivity for OBI-1 in the European Union after its marketing approval. Ipsen licensed OBI-1 to Inspiration Biopharmaceuticals under an
Chugai said that the Phase III study was a randomised, double-blind, parallel-group, comparative study to compare the 3-year incidence of bone fractures and the safety of eldecalcitol with
ADL5945, licensed from Eli Lilly and Company in 2009, is a proprietary, peripherally-acting mu opioid receptor antagonist. Adolor plans to recruit about 120 patients in the trial, to
Allist will fund the development costs required for the regulatory approval in China for the two products. Under the agreement, Allist undertakes to perform development activities according to
Gliclazide is commonly used to control mild to moderate adult-onset type 2 diabetes. Lotus Pharma’s new controlled-release Gliclazide tablet is formulated using osmotic pump technology, which encases the
PPG’s packaging coatings are used for containers for the pharmaceutical, beverage, food, cosmetic, paint and chemical industries. Approximately 70 Bairun employees involved with sales, research and development, quality
As per the agreement, PSI will use Solumer technology to develop drug products for SoluBest’s clients. PSI expects to provide Solumer formulation and clinical trial supply manufacturing to
Bydureon, an investigational, extended-release medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose, is the proposed brand name for
AMP is a full service cGMP drug, device and combination product contract manufacturer providing developmental, clinical and commercial contract manufacturing services to large and small organisations. AMP president
Forest Laboratories posted a net income of $286.11m for the third quarter 2010, or $1 per diluted share, compared to $186.66m, or $0.61 per diluted share, for the